Silver Book Fact

TAVR improves quality of life in SAS patients

Fact image

Kovac J, Schuler G, Gerckens U, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8). https://www.pcronline.com/eurointervention/105th_issue/volume-12/number-8/169/four-year-experience-with-the-corevalve-transcatheter-heart-valve.html

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, et al
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Survival rates of SAS patients ages 80+ with and without SAVR
     
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states